Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
BEN heads into its November 6 earnings date with short interest creeping higher, options traders at a defensive extreme, and the Street deeply split on whether UBS's bullish re-entry is early or exactly right.
The most telling signal this week is in options. Demand for downside protection has moved well beyond normal levels. The put/call ratio reached 0.63 on Monday, more than two standard deviations above its 20-day average of 0.55. That is the most elevated reading since last year's 52-week peak of 1.04, and it has held near that level for three consecutive sessions. The stock itself has dropped 3.9% over the past week to $31.18, now nearly 9 points below UBS's $40 target from last week. The gap between where the most bullish analyst on the Street is pointing and where the market is actually trading captures the tension around BEN right now.
Short positioning is building, though not yet alarming. At 3.3% of free float, short interest is modest in absolute terms. It has risen roughly 3% over the past week and 11.5% over the past month, a steady grind upward that implies growing conviction among bears rather than a sudden tactical bet. The borrow market remains completely uncontested. Availability is running at over 1,500% of current short interest, meaning there are roughly fifteen shares available to borrow for every one currently borrowed. Cost to borrow is under 0.50%, near its lowest level of the past six weeks. There is no squeeze pressure here: anyone who wants to be short can get short cheaply, and the expanding SI reflects that ease.
The analyst picture is where the real argument plays out. UBS's Michael Brown assumed coverage on October 7 with a Buy and a $40 target, a striking 74% lift from the prior analyst's level, and the most aggressive single move on BEN in the recent note. The rest of the Street has gone in the other direction this week. Barclays cut to $34 from $36 (Equal-Weight). TD Cowen trimmed to $38 from $40, holding Buy. JP Morgan nudged its Neutral target up a dollar to $35. Evercore ISI maintained an Underperform with a $35 target. The consensus mean sits at $35.46, implying about 14% upside from Tuesday's close, but the distribution of views is unusually wide. Factor scores add some texture. EPS momentum is genuinely strong, ranked in the 91st percentile on a 90-day basis and 96th on a 30-day basis. The analyst recommendation differential scores in the 98th percentile, which reflects how many upgrades relative to downgrades the stock has seen. Dividend scoring also ranks in the 97th percentile, a reminder that at current prices BEN's yield is meaningful to income-oriented buyers. Against that, the short score ranks only in the 33rd percentile and EPS surprise ranks in the 29th, neither of which supports the more aggressive bull case.
Ownership is dominated by the founding Johnson family, which collectively holds well over 40% of shares between Rupert Johnson, Charles Johnson, Jennifer Johnson (CEO), and Gregory Johnson (Executive Chairman). The institutional register is stable. BlackRock and State Street both added modestly in the September quarter. Power Corporation of Canada cut its stake by over six million shares through June, and Invesco trimmed by 1.4 million. The activist register has no 13D filers. The recent insider filings are all transaction-code F (tax withholding on vesting), not open-market sales, and should not be read as discretionary conviction. Net insider activity is flat over the past 90 days.
The last earnings print, on July 31, saw BEN jump 6.2% on the day and hold much of that move over the following week. November 6 is now 23 days away. Between now and then, the question is whether the options-driven defensiveness fades as BEN stabilises, or whether the put/call ratio and the continued short-interest build start to reinforce each other as the print approaches.
See the live data behind this article on ORTEX.
Open BEN on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
